60 Degrees Pharmaceutical...
(SXTP)
undefined
undefined%
At close: undefined
1.40
1.45%
After-hours Dec 13, 2024, 07:50 PM EST
Company Description
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases.
The company offers Arakoda for malaria preventative treatment.
It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue.
The company was founded in 2010 and is based in Washington, District of Columbia.
60 Degrees Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Jul 12, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Dr. Geoffrey Stuart Dow |
Contact Details
Address: 1025 Connecticut Avenue NW Washington, DC United States | |
| Website | https://60degreespharma.com |
Stock Details
| Ticker Symbol | SXTP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001946563 |
| CUSIP Number | 83006G104 |
| ISIN Number | US83006G1040 |
| Employer ID | 45-2406880 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Geoffrey Stuart Dow | Chairman, Chief Executive Officer & President |
| Tyrone Miller | Chief Financial Officer & Treasurer |
| Dr. Bryan Smith | Chief Medical Officer |
| Jennifer Herz | Director |
| Kristen Landon | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 09, 2024 | 4 | Filing |
| Nov 21, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 06, 2024 | 8-K | Current Report |
| Oct 15, 2024 | DEF 14A | Filing |
| Oct 08, 2024 | 8-K | Current Report |
| Oct 02, 2024 | PRE 14A | Filing |
| Sep 19, 2024 | S-3 | Filing |